The first visit matters more than most clinicians give it credit for. A GLP-1 prescription written without a thorough conversation is not just a missed clinical opportunity — it's a setup for poor outcomes, medication abandonment, unrealistic expectations, and patients who are left alone to navigate one of the most significant metabolic interventions of their lives.
In my practice, the first visit is the foundation for everything that follows. The goal isn't just to determine whether a patient is a clinical candidate. It's to ensure they understand what this medication is, what it isn't, what will be required of them, what to expect when things get hard, and — perhaps most importantly — to address the shame and stigma that so many of my patients carry before they ever walk through the door.
This article outlines the framework I use. It's designed to be practical for providers and readable for patients.
Obesity is a disease — not a willpower problem
Before anything else — before reviewing labs, before discussing dosing, before talking about insurance — I address something that a surprising number of my patients need to hear directly: seeking treatment for obesity is not an admission of personal failure. It is the same as seeking treatment for hypertension, diabetes, or any other chronic disease. And it deserves the same clinical seriousness.
Many of my patients arrive with significant ambivalence about starting a GLP-1. They've internalized decades of cultural messaging that equates body weight with discipline, self-control, and moral character. They feel like they should have been able to do this on their own. They worry that using medication is somehow cheating, or that it means they've given up.
"You would never say, 'Your cancer came back — you didn't try hard enough.' We have applied exactly that logic to obesity for generations. GLP-1 medications are helping us finally replace assumption with clear pathology." — Dr. Daniel Drucker, University of Toronto, endocrinologist who researched GLP-1 in the 1990s
The science is unambiguous: obesity is a complex, chronic, neurometabolic disease. The WHO recognized it as such and issued formal GLP-1 treatment guidelines in December 2025, emphasizing that it requires lifelong, person-centered care — not willpower. The biology driving excess body weight involves disrupted hormonal signaling, altered reward pathways in the brain, genetic predisposition, environmental factors, and metabolic adaptation — none of which are overcome by trying harder.
If you are considering a GLP-1 medication but feel conflicted about it, I want to offer you something that the internet rarely does: you are not a failure. The fact that you have struggled to lose weight and keep it off does not reflect a deficit in your character. It reflects the biology of a chronic disease that is extraordinarily difficult to treat without medical support.
Here is a simple piece of evidence: many patients who start GLP-1 medications describe an almost overnight reduction in "food noise" — the constant, intrusive mental preoccupation with food that has followed them for years. This doesn't happen because the medication strengthened their willpower. It happens because GLP-1 receptors in the brain's reward and satiety centers are literally quieting signals that were dysregulated. That is not a character story. That is neurobiology.
Research shows that GLP-1 directly reduces activity in the brain regions responsible for food reward — the insula, amygdala, and orbitofrontal cortex — independently of any behavioral change. The brain was always driving this. You were not failing to try hard enough. You were working against a biological current. This medication helps correct that current. Accepting that help is not weakness. It is good medicine.
The medication is a tool — not the solution
Having addressed the stigma piece, the second thing I establish clearly is the other side of the equation: this medication is an extraordinarily powerful tool, but it is not a passive one. It creates conditions under which meaningful change is possible. It does not make that change automatically.
GLP-1 medications suppress appetite, reduce food noise, slow gastric emptying, and improve insulin signaling. What they do not do is build muscle, optimize your protein intake, manage your stress, ensure you're sleeping, or guarantee long-term weight maintenance on their own. The medication creates the window. The patient's actions determine what happens in it.
I frame this explicitly at the first visit and revisit it at every subsequent one. The goal is not to make patients feel burdened by this — it's to give them agency. The medication is working for you. Here is what you can do to work with it.
🩺 Provider note
Studies consistently show that GLP-1 medications produce significantly better long-term outcomes when combined with structured behavioral and lifestyle intervention. The 2025 WHO guidelines issued a conditional recommendation for intensive behavioral therapy as a co-intervention alongside GLP-1 treatment. This doesn't mean every patient needs a formal program — but it does mean that prescribing without any lifestyle counseling is clinically inadequate. Document the counseling you provide. It matters both for outcomes and for insurance coverage requirements.
Screening for patient readiness
Not every patient who wants a GLP-1 prescription is ready to start one. A core part of the first visit is an honest, non-judgmental assessment of where the patient actually is — and whether now is the right time.
The questions I find most useful in this conversation:
- What does a typical day of eating look like for you right now? If a patient is currently eating once a day or skipping meals regularly, they are not ready to navigate the appetite suppression of a GLP-1 safely.
- What is your current relationship with meal timing? Patients who have no established eating structure will struggle to hit protein targets and maintain adequate nutrition on a medication that significantly reduces the drive to eat.
- What changes are you willing and able to make starting now? Not in six months when you feel better — now, before the first injection.
- What does your support system look like? Is their household aligned with the changes this will require, or will they be navigating it alone?
- What is your current stress level and work-life balance? Chronic high stress is both a driver of weight gain and a barrier to the consistent eating and lifestyle habits this medication requires.
Your provider asking these questions is not gatekeeping — it's good care. If the honest answer is that you are currently eating one meal a day, skipping breakfast, working 12-hour days, and have no capacity to prioritize your nutrition, then the most helpful thing may not be starting the medication immediately. It may be spending the next 4–8 weeks building the habits and structure that will make the medication work for you rather than against you.
This is not a punishment or a test you can fail. It's an investment. The medication will be there when you're ready. Starting when you're not ready tends to result in poor nutrition, muscle loss, frustrating outcomes, and a conviction that the medication "didn't work" — when the real issue was timing.
Red flags that suggest delaying prescribing
⚠️ Consider delaying or pausing before prescribing if:
- The patient is currently skipping most meals and has no plan to change this
- Active, untreated disordered eating (restriction, bingeing, purging) — GLP-1s require specialist co-management in this context
- Acute untreated depression or significant psychiatric instability — establish a mental health baseline and ensure treatment is in place first
- Active alcohol use disorder or substance use that has not been discussed with their treatment team
- No social or practical support structure for the lifestyle changes required
- Patient is unwilling to commit to any dietary or lifestyle change — the medication alone is unlikely to produce durable results
- Pregnancy or planning to conceive in the near term
- Personal or family history of medullary thyroid cancer or MEN2 (contraindication)
- History of pancreatitis — evaluate carefully before prescribing
Labwork: what to order and why
Baseline labwork before starting a GLP-1 serves three purposes: it identifies conditions that may affect treatment decisions, it documents the comorbidities that support medical necessity for insurance coverage, and it establishes a baseline for tracking metabolic improvement over time. The more recent the better — most insurers want labs within the past 6–12 months, and some require them within the past 90 days.
Encourage your patients to get updated labwork before their first visit, or order it at the first visit so results are available before the prescription is finalized. This is one of the most practical things patients can do to support their own coverage approval.
| Lab | Priority | Why it matters for GLP-1 prescribing |
|---|---|---|
| HbA1c | Required | Establishes diabetes/prediabetes status; critical for insurance; guides medication choice (Ozempic vs Wegovy pathway) |
| Comprehensive metabolic panel (CMP) | Required | Assesses kidney and liver function; identifies electrolyte abnormalities; baseline before starting |
| Lipid panel | Required | Documents dyslipidemia as a comorbidity for PA; GLP-1s improve lipid profiles — good to track improvement |
| CBC (complete blood count) | Required | Screens for anemia, especially important given protein/nutrition demands on the medication |
| TSH (thyroid panel) | Required | Hypothyroidism causes weight gain and hair loss — critical to rule out before attributing symptoms to GLP-1; also a contraindication screen |
| Fasting glucose | Recommended | Pairs with HbA1c for complete metabolic picture; useful for insurance documentation |
| Ferritin / iron panel | Recommended | Iron deficiency drives hair loss and fatigue — common on GLP-1s due to reduced intake; important baseline |
| Vitamin D | Recommended | Deficiency is common in obesity and worsens with reduced dietary intake on the medication |
| Uric acid | Recommended | Rapid weight loss can trigger gout flares — baseline useful if patient has history or risk |
Insurance and prior authorization basics
Insurance coverage for GLP-1 medications is one of the most variable and frustrating aspects of prescribing them. Coverage is not universal, approval rates vary dramatically, and a poorly documented submission is one of the most common causes of denial. Setting realistic expectations about this process at the first visit prevents a lot of downstream frustration for both patient and provider.
- BMI ≥30, or BMI ≥27 with at least one qualifying comorbidity
- Common comorbidities: hypertension, T2DM, prediabetes, dyslipidemia, OSA, CVD
- Documentation of prior weight loss attempts (diet, exercise, sometimes prior medications)
- Recent labs — HbA1c, lipid panel, BMI measurements on at least two dates
- Some plans require 3–6 months in a supervised weight management program
- Step therapy: some plans require trial of Saxenda before Wegovy
- Recent labs (within 90 days where possible)
- ICD-10 codes for all qualifying comorbidities — document them explicitly
- Weight history documented across multiple chart visits
- Narrative letter of medical necessity addressing why GLP-1 is appropriate
- Documentation of lifestyle counseling provided at this visit
- Prior medication trials listed with outcomes and reasons for discontinuation
Setting realistic weight loss expectations
Patients frequently arrive having read about dramatic weight loss results online. Some expect to lose 20% of their body weight within months. Some expect results identical to those in clinical trials. The first visit is the right time to calibrate these expectations — not to dampen enthusiasm, but to prevent the discouragement that comes from measuring real progress against an unrealistic benchmark.
Key points to cover at the first visit on expectations:
- Results are not linear. Patients often lose weight quickly in the first few months, plateau, and then experience slower or more variable progress. This is normal and expected.
- Clinical trial numbers are averages from highly controlled populations with intensive behavioral support. Real-world results are typically somewhat lower.
- The first 4–8 weeks are primarily about tolerability, not weight loss. This is the dose escalation phase. Some patients lose little weight in this period and should not interpret this as failure.
- 5–10% body weight loss is clinically meaningful. It improves blood pressure, blood sugar, lipids, sleep apnea, and joint pain — often dramatically. Frame success around health outcomes, not just the number on the scale.
- Weight loss typically slows and eventually plateaus around 12–18 months. This is a biological adaptation, not failure. It is a conversation to have proactively so patients aren't blindsided.
Managing side effect expectations
Nausea, constipation, and reduced appetite are the most commonly reported early side effects, and the most common reasons patients discontinue before reaching an effective dose. Patients who are prepared for these effects and have practical strategies for managing them are significantly more likely to push through the adjustment period.
- Nausea — most common in weeks 1–4 and after each dose increase; typically improves
- Constipation — very common; hydration and fiber (tolerated) are first-line
- Reduced appetite — the intended effect, but can be too aggressive early on
- Fatigue — common in the first few weeks as the body adjusts
- Injection site reactions — generally mild and transient
- Burping, reflux, or bloating — related to slowed gastric emptying
- Eat smaller portions, more slowly — do not override the satiety signal
- Avoid high-fat, greasy, or very spicy foods especially around dosing days
- Stay well hydrated — dehydration worsens nausea and constipation
- If nausea is severe, consider dose timing (evening vs morning injections)
- Don't escalate the dose while side effects are unmanaged — tell your provider
- Protein shakes can replace solid protein on difficult days around injection
I also tell my patients explicitly that nausea that prevents them from eating or drinking adequately is not something to push through alone. That is a call to my office. Persistent vomiting, signs of dehydration, or severe abdominal pain warrant immediate evaluation.
Mental health baseline screening
A mental health baseline is a standard part of my first GLP-1 visit — not because these medications are dangerous for most patients with psychiatric histories, but because the interaction between weight, appetite, mood, and medication deserves clinical attention from day one.
At minimum, I ask about and document:
- Current or recent history of depression or anxiety
- Current psychiatric medications — particularly antidepressants, mood stabilizers, and benzodiazepines
- History of disordered eating or eating disorders
- Current alcohol and substance use
- Any history of suicidal ideation or self-harm
🩺 Provider note on neuropsychiatric monitoring
The FDA reviewed and ultimately removed a formal suicidal ideation warning from GLP-1 medications following its 2026 meta-analysis, which did not establish a causal link. However, clinical vigilance remains appropriate — particularly for patients on concurrent antidepressants or benzodiazepines, where pharmacovigilance data has suggested a possible signal. Document baseline mood status. Counsel patients to report mood changes promptly — and specifically tell them that if they notice mood shifts while on the medication, they should contact you before making any changes to their psychiatric medications. What feels like a need to adjust an antidepressant may be GLP-1-related and may resolve on its own.
Separately, many patients experience positive mood changes on GLP-1 medications — reduced anxiety around food, improved self-perception as weight loss progresses, and reduced brain preoccupation with eating. These are worth acknowledging and monitoring as well.
What happens if the medication is stopped
This conversation needs to happen at the first visit — not at month 12 when a patient's insurance drops their coverage or they decide to take a break. Weight regain after GLP-1 discontinuation is not a side effect or a failure of the medication. It is the expected biological consequence of stopping treatment for a chronic disease.
Clinical trial data is consistent: approximately 50–65% of total weight lost on semaglutide or tirzepatide is regained within one year of stopping the medication, even with continued lifestyle support. This mirrors what happens when you stop blood pressure medication — the disease doesn't go away because the treatment was effective.
I tell patients: "We are treating a chronic disease. This medication works as long as you take it, just as a blood pressure medication works as long as you take it. If you stop it, your brain's appetite regulation will return to its prior state, and for most people that means weight gradually comes back. This doesn't mean the medication failed. It means obesity is a disease that requires ongoing management."
The goal is not to frighten patients into staying on the medication indefinitely. Some patients will reach a stable weight and be able to maintain it with lifestyle alone. Some will need the medication long-term. Both are legitimate outcomes. But patients deserve to make this decision with full information — not to stop the medication thinking they're "done" and then feel like they've failed when weight returns.
Follow-up visit cadence
The first 3–6 months of GLP-1 treatment are the highest-risk period for poor nutrition, inadequate protein intake, muscle loss, and dose-related side effects. This is precisely when follow-up is most critical — and most often neglected in busy practices.
At each follow-up, I explicitly ask about protein intake. If a patient cannot tell me approximately how much protein they're eating per day, that is a clinical gap that needs addressing — not a question to skip in the interest of time. Patients who are consistently meeting protein targets and doing some form of resistance training are the ones who are losing fat rather than muscle, and who maintain their results most durably.
Consider pausing dose increases for any patient who is not meeting basic nutritional targets. Escalating the dose while a patient is nutritionally adrift is not in their long-term interest. Adequate protein intake and consistent eating habits should be a prerequisite for upward titration, not an afterthought.
First-visit checklist for providers
The following checklist summarizes the key elements of a comprehensive GLP-1 first visit. It is designed to be printed and used as a reference during the visit, or adapted into your own intake documentation.
🗒️ GLP-1 First Visit — Clinical Checklist
References and sources
- Celletti F, Farrar J, De Regil L. World Health Organization guideline on the use and indications of glucagon-like peptide-1 therapies for the treatment of obesity in adults. JAMA. 2026;335(5):434–438. doi:10.1001/jama.2025.24288
- Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Am J Clin Nutr. 2025. doi:10.1016/j.ajcnut.2025.04.023
- American Diabetes Association. Standards of Care in Diabetes–2026. Section 8: Obesity and Weight Management. Diabetes Care. 2026;49(Suppl 1):S166–S190. Full text
- Drucker DJ. GLP-1 and the neurobiology of eating control: recent advances. Endocrinology. 2025;166(2):bqae167. doi:10.1210/endocr/bqae167
- Van Bloemendaal L, et al. GLP-1 receptor agonist liraglutide significantly reduces food reward and improves emotional well-being: insights from neuroimaging. Neuroimage. 2014.
- Ard J, et al. Beyond weight loss: GLP-1 usage and appetite regulation in the context of eating disorders and psychosocial processes. Nutrients. 2025;17(23):3735. doi:10.3390/nu17233735
- Diktas HE, et al. Development and validation of the Food Noise Questionnaire. Obesity. 2025;33:289–297. doi:10.1002/oby.24216
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989–1002.
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205–216.
- Aronne LJ, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025;393(1):26–36.
- WHO. WHO issues global guideline on the use of GLP-1 medicines in treating obesity. December 1, 2025. who.int
- FDA Drug Safety Communication. FDA requests removal of suicidal behavior and ideation warning from GLP-1 RA medications. January 2026. fda.gov
- CMS. Medicare GLP-1 Bridge coverage criteria. 2026. cms.gov